Business Wire

Citynet deploys ADVA ALM for comprehensive fiber monitoring

4.12.2019 11:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that Citynet (HALL AG Kommunal GmbH) has deployed the ADVA ALM fiber monitoring solution in its backbone network. The technology is now enhancing performance and reducing operating costs in the municipal utility and telecommunications provider’s infrastructure. With real-time insight into its fiber network, Citynet is able to rapidly locate and repair fiber breaks with minimal disruption, reducing truck rolls, lowering carbon footprint and improving sustainability. The solution ensures optimal service at carrier handover points and supports the delivery of high-value SLAs. Technical support and maintenance is provided by ADVA’s partner Componet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005060/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA's ALM technology is helping Citynet to reduce its carbon footprint (Photo: Business Wire)

“The ADVA ALM enables our repair teams to quickly detect and pinpoint any degradation in our fiber plant. It means no more wasted hours on futile site visits. With proactive maintenance we can also resolve many more issues before services are affected so that outages can be avoided altogether. In fact, the ADVA ALM is so effective that we expect the amortization within the coming months,” said Manuel Kofler, head of IT division, Citynet. “This simple device helps us deliver unbeatable performance and increase the value of our SLAs. Yet it’s the boost to sustainability that makes the ADVA ALM valuable both now and in the future. Reducing truck rolls is key to tackling our carbon footprint and protecting our environment in the long term.”

The ADVA ALM is now proactively assuring Citynet’s fiber infrastructure throughout western Austria. Built on the ADVA FSP 3000 platform and FSP 150 multi-layer edge technology, the regional backbone network is fully protected by round-the-clock service-agnostic monitoring and managed by ADVA’s powerful and easy-to-use Ensemble Controller. Now, Citynet can instantly and precisely locate breaks that could threaten mission-critical services. Maintenance teams can also quickly ascertain whether impairments are in Citynet’s own fiber plant or on a carrier’s side of the network. What’s more, ADVA’s passive sensors are deployed in sites with no available power for remote link monitoring of utility holes and ducts.

“Our unique monitoring technology has already had a significant impact on Citynet’s network and on the people who depend on it. With proactive, in-service monitoring of the integrity and performance of its fiber, Citynet is guaranteeing availability and safeguarding vital services,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “Working closely with its team, we’ve helped Citynet to transform its municipal fiber network into a truly sustainable infrastructure. With our ALM solution, it can concentrate on what it does best, producing sustainable energy and delivering high-quality services, safe in the knowledge that its network is continually monitored and running at maximum efficiency.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla to Meet With Mobile Game Developers and Publishers at Pocket Gamer Connects Barcelona 202611.6.2026 16:00:00 EEST | Press release

Xsolla, a leading global video game commerce company, today announced its participation in Pocket Gamer Connects (PGC) Barcelona 2026, taking place June 15-16 at the Hyatt Regency Barcelona in Barcelona, Spain. Xsolla will be on the ground for meetings with mobile game developers, publishers, and strategic partners, bringing its direct-to-consumer commerce infrastructure to one of the most deal-focused events in the European games calendar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611487209/en/ Graphic: Xsolla Now in its second year, PGC Barcelona has quickly established itself as a destination conference for mobile game businesses, drawing more than 1,000 attendees from over 47 countries and facilitating thousands of structured business meetings through its dedicated matchmaking platform. Barcelona itself has become one of Europe's most significant gaming cities, home to studios including Scopely, King, Rovio, Band

Onera Will Showcase Its Onera hPSG® Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.11.6.2026 16:00:00 EEST | Press release

Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2026 conference. The medtech company will showcase this innovative solution at booth #600 during the largest annual sleep medicine conference, which brings together leading experts and innovators in the field. Furthermore, in anticipation of new CPT codes, Onera Health will host an educational symposium on Scaling PSG for the Next Decade: Expanding Utilization of High-Complexity Home Testingon Monday, June 15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611302332/en/ Onera hPSG® – Bringing PSG Home. “We are excited to see our Onera hPSG® solution highlighted at this important meeting in three different presentations and an educational seminar. Onera hPSG® is positioned to be an integral par

IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 15:50:00 EEST | Press release

The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The installation, located at the CINECA headquarters in the DAMA Tecnopolo in Bologna, represents not just technological progress but a strategic Italian asset providing concrete tools for the scientific community and businesses to foster innovation, accelerate research, and transform knowledge into high-impact applications.

Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release

The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye